This Schedule 14A filing consists of communications from Paratek Pharmaceuticals, Inc., a Delaware
corporation (the Company), to the Companys stockholders relating to the Agreement and Plan of Merger, dated June 6, 2023, by and among the Company, Resistance Acquisition, Inc., a Delaware corporation (Parent) and
Resistance Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the Merger Agreement).
On August 14,
2023, the Company made updates to its website (www.paratekpharma.com) in connection with the Companys special meeting of stockholders occurring virtually on September 18, 2023, at 9 a.m. Eastern Time. Screenshots of the new and updated
web pages can be found below:
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ
materially from those implied by the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current
expectation of Paratek Pharmaceuticals, Inc. (the Company) and members of its senior management team and can typically be identified by words such as believe, expect, estimate, predict,
target, potential, likely, continue, ongoing, could, should, intend, may, might, plan, seek,
anticipate, project and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions,
prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Companys business; the commercial success of the Companys products; the timing of and receipt of filings and
approvals relating to the proposed transaction; the expected timing of the completion of the proposed transaction; the ability to complete the proposed transaction considering the various closing conditions; and the accuracy of any assumptions
underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking
statements include: uncertainties as to the timing of the merger; uncertainties as to how many of the Companys stockholders will vote their stock in favor of the proposed transaction; the occurrence of any event, change or other circumstance
that could give rise to the termination of the Agreement and Plan of Merger, dated as of June 6, 2023, among the Company, Resistance Merger Sub, Inc. (Merger Sub) and Resistance Acquisition, Inc. (the Merger Agreement),
including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the satisfaction of the conditions
precedent to the consummation of the proposed transaction, including the ability to secure stockholder approval on the terms expected, at all or in a timely manner; the effects of the transaction (or the announcement or pendency thereof) on
relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities; transaction costs; the risk that the
merger will divert managements attention from the Companys ongoing business operations or otherwise disrupt the Companys ongoing business operations; changes in the Companys businesses during the period between now and the
closing; certain restrictions during the pendency of the proposed transaction that may impact the Companys ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the proposed
transaction; the Companys ability to continue as a going concern; the Companys ability to maintain or expand regulatory approvals or commercialize the Companys products; the results of any ongoing or future clinical trials may not
satisfy U.S. or non-U.S. regulatory authorities; the regulatory approval process is expensive, time consuming and uncertain; the Companys dependence on the commercialize success of NUZYRA and, to a
lesser extent, SEYSARA; the Companys dependence on funding from BARDA; the Companys substantial indebtedness; risk associated with litigation; the uncertainty associated with the current worldwide economic conditions and the continuing
impact on economic and financial conditions in the United States and around the world, including as a result of COVID-19, rising inflation, increasing interest rates, natural disasters, military conflicts,
including the conflict between Russia and Ukraine, terrorist attacks and other similar matters, and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including current reports on Form 8-K,